Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  





2 Side effects  



2.1  Tolerance  





2.2  Other side effects  







3 Mechanism of action  





4 Society and culture  





5 References  














Isosorbide dinitrate






العربية
تۆرکجه
Deutsch
Español
Euskara
فارسی
Français
Bahasa Indonesia
Italiano
עברית
Magyar
ି
Polski
Português
Русский
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi

Українська
Tiếng Vit

 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Isosorbide dinitrate
Clinical data
Trade namesIsordil, others[1]
Other namesISDN; (3R,3aS,6S,6aS)-hexahydrofuro[3,2-b]furan-3,6-diyl dinitrate
AHFS/Drugs.comMonograph
MedlinePlusa682348
License data
Pregnancy
category
  • AU: B1
  • Routes of
    administration
    By mouth
    ATC code
    Legal status
    Legal status
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Bioavailability10–90%, average 25%
    MetabolismLiver
    Elimination half-life1 hour
    ExcretionKidney
    Identifiers
    • 1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol

    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.001.583 Edit this at Wikidata
    Chemical and physical data
    FormulaC6H8N2O8
    Molar mass236.136 g·mol−1
    3D model (JSmol)
    • [O-][N+](=O)O[C@H]1[C@H]2OC[C@H](O[N+]([O-])=O)[C@H]2OC1

    • InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1 checkY

    • Key:MOYKHGMNXAOIAT-JGWLITMVSA-N checkY

     ☒NcheckY (what is this?)  (verify)

    Isosorbide dinitrate is a medication used for heart failure, esophageal spasms, and to treat and prevent chest pain from not enough blood flow to the heart.[1] It has been found to be particularly useful in heart failure due to systolic dysfunction together with hydralazine.[2][1] It is taken by mouth or under the tongue.[1]

    Common side effects include headache, lightheadedness with standing, and blurred vision.[1] Severe side effects include low blood pressure.[1] It is unclear if use in pregnancy is safe for the baby.[1] It should not be used together with PDE5 Inhibitors.[1] Isosorbide dinitrate is in the nitrate family of medications and works by dilating blood vessels.[1]

    Isosorbide dinitrate was first written about in 1939.[3] It is on the World Health Organization's List of Essential Medicines.[4] Isosorbide dinitrate is available as a generic medication.[1][5] A long-acting form exists.[1] In 2021, isosorbide was the 111th most commonly prescribed medication in the United States, with more than 5 million prescriptions.[6][7]

    Medical uses[edit]

    It is used for angina, in addition to other medications for congestive heart failure, and for esophageal spasms.[1] It is available as an oral tablet both in extended release and slow release. The onset of action for Isosorbide Dinitrate is thirty minutes and the onset of action for oral extended release is 12–24 hours.

    Long-acting nitrates can be more useful as they are generally more effective and stable in the short term.

    Side effects[edit]

    Tolerance[edit]

    After long-term use for treating chronic conditions, tolerance may develop in patients, reducing its effectiveness. The mechanisms of nitrate tolerance have been thoroughly investigated in the last 30 years and several hypotheses have been proposed. These include:

    1. Impaired biotransformation of isosorbide dinitrate to its active principle NO (or a NO-related species)
    2. Neurohormonal activation, causing sympathetic activation and release of vasoconstrictors such as endothelin and angiotensin II which counteract the vasodilation induced by isosorbide dinitrate
    3. Plasma volume expansion
    4. The oxidative stress hypothesis[8]

    The last hypothesis might represent a unifying hypothesis, and an isosorbide dinitrate-induced inappropriate production of oxygen free radicals might induce a number of abnormalities which include the ones described above. Furthermore, nitrate tolerance is shown to be associated with vascular abnormalities which have the potential to worsen patients prognosis:[9] these include endothelial and autonomic dysfunction.[10]

    Other side effects[edit]

    In the short run, isosorbide dinitrate can cause severe headaches, necessitating analgesic administration for relief of pain, as well as severe hypotension, and, in certain cases, bradycardia.

    Rarely occurring are allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); fainting; fast or slow heartbeat; nausea; new or worsening chest pain; vomiting.

    Mechanism of action[edit]

    Similar to other nitrites and organic nitrates, isosorbide dinitrate is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase (atrial natriuretic peptide receptor A). This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent sequestration of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.[11]

    Society and culture[edit]

    Isosorbide dinitrate is sold in the US under the brand names Dilatrate-SR by Schwarz and Isordil by Valeant, according to FDA Orange Book. It is sold under the trade name Isoket in the United Kingdom, Argentina, and Hong Kong. It is also a component of BiDil.

    References[edit]

    1. ^ a b c d e f g h i j k l "Isosorbide Dinitrate/Mononitrate". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
  • ^ Chavey WE, Bleske BE, Van Harrison R, Hogikyan RV, Kesterson SK, Nicklas JM (April 2008). "Pharmacologic management of heart failure caused by systolic dysfunction". American Family Physician. 77 (7): 957–964. PMID 18441861.
  • ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 454. ISBN 9783527607495. Archived from the original on 20 December 2016.
  • ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  • ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  • ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  • ^ "Isosorbide - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  • ^ Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG (January 1995). "Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance". The Journal of Clinical Investigation. 95 (1): 187–94. doi:10.1172/JCI117637. PMC 295403. PMID 7814613.
  • ^ Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C (September 1999). "Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group". American Heart Journal. 138 (3 Pt 1): 577–85. doi:10.1016/s0002-8703(99)70163-8. PMID 10467211.
  • ^ Gori T, Parker JD (July 2008). "Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs". Journal of the American College of Cardiology. 52 (4): 251–4. doi:10.1016/j.jacc.2008.04.019. PMID 18634978.
  • ^ Rang HP, Ritter J, Flower RJ, Henderson G (2016). Pharmacology (8th ed.). Elsevier. p. 261. ISBN 978-0-7020-5362-7.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Isosorbide_dinitrate&oldid=1204454392"

    Categories: 
    Nitrate esters
    Antianginals
    Furofurans
    World Health Organization essential medicines
    Drugs developed by Wyeth
    Drugs developed by Pfizer
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Use dmy dates from February 2024
    Drugs with non-standard legal status
    Articles with changed EBI identifier
    ECHA InfoCard ID from Wikidata
    Drugboxes which contain changes to verified fields
    Drugboxes which contain changes to watched fields
    Wikipedia medicine articles ready to translate
     



    This page was last edited on 7 February 2024, at 04:42 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki